NASDAQ:KLRS
Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. reported net income of −$43.4M in fiscal 2025. Free cash flow was −$38.6M, and the diluted share count rose 1042.9%.Summary generated from Kalaris Therapeutics, Inc.'s SEC filings. Latest annual report filed Mar 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$38.6M
FCF marginn/a
Share count change+1042.9%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | −170 | −171 | −200 | −52 | −46 |
| Net income | −172 | −169 | −190 | −69 | −43 |
| Free cash flow | −106 | n/a | n/a | n/a | −39 |
Recent filings
- 4Insider transaction report
Aug 28, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 11, 2026 - 8-KResults of operations and financial condition
Aug 11, 2026 - 4Insider transaction report
Aug 3, 2026 - 8-KDirector or officer change
Jul 20, 2026 - 8-KRegulation FD disclosure
Jul 17, 2026 - 8-KDirector or officer change
Jul 6, 2026 - 8-KResults of a shareholder vote
Jun 4, 2026